Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $276.51.

  • Zhengye Biotechnology Holding's Short-term Investments changed N/A to $276.51 in Q2 2025 from the same period last year, while for Jun 2025 it was $276.51, marking a year-over-year change of. This contributed to the annual value of $278.34 for FY2024, which is 9998.38% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Short-term Investments stood at $276.51 for Q2 2025.
  • Zhengye Biotechnology Holding's Short-term Investments' 5-year high stood at $1.7 million during Q4 2023, with a 5-year trough of $276.51 in Q2 2025.
  • Its 3-year average for Short-term Investments is $560966.0, with a median of $278.43 in 2024.
  • Data for Zhengye Biotechnology Holding's Short-term Investments shows a peak YoY increase of 9998.34% (in 2024) and a maximum YoY decrease of 9998.34% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Short-term Investments (Quarter) stood at $1.7 million in 2023, then crashed by 99.98% to $278.43 in 2024, then dropped by 0.69% to $276.51 in 2025.
  • Its last three reported values are $276.51 in Q2 2025, $278.43 for Q4 2024, and $1.7 million during Q4 2023.